Form 4: Cumberland Pharmaceuticals Director Kenneth Krogulski Acquires Shares
SEC Form 4 Filing
Director Kenneth Krogulski reports acquisition of Cumberland Pharmaceuticals shares via restricted stock award.
Summary
- On March 17, 2025, Kenneth Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), acquired 1,000 shares of common stock at a price of $5.17 per share.
- Additionally, Krogulski acquired 4,000 shares of common stock at the same price of $5.17 per share.
- These transactions increased Krogulski's direct ownership to 282,843 shares.
- The shares were acquired through a restricted stock award that will vest 100% on March 17, 2026.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by a director. The acquisition itself could be seen as slightly positive, indicating confidence, but the filing is purely informational.
Positives
- Director's acquisition of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of stock acquisition. |
| 03/17/2026 | Vesting date of the restricted stock award. |
| 03/18/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.